Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Niluka De Mel"'
Autor:
Yue Huang, Jiaqi Yuan, Ruipeng Mu, Robert J. Kubiak, Kathryn Ball, Mingyan Cao, G. Patrick Hussmann, Niluka de Mel, Dengfeng Liu, Lorin K. Roskos, Meina Liang, Anton I. Rosenbaum
Publikováno v:
Antibodies, Vol 12, Iss 4, p 66 (2023)
Deamidation, a common post-translational modification, may impact multiple physiochemical properties of a therapeutic protein. MEDI7247, a pyrrolobenzodiazepine (PBD) antibody–drug conjugate (ADC), contains a unique deamidation site, N102, located
Externí odkaz:
https://doaj.org/article/b0bf267e4c2342369ff9562c70aa3c06
Autor:
Mingyan Cao, G. Patrick Hussmann, Yeqing Tao, Ellen O’Connor, Conner Parthemore, Diana Zhang-Hulsey, Dengfeng Liu, Yang Jiao, Niluka de Mel, Meagan Prophet, Samuel Korman, Jaytee Sonawane, Christina Grigoriadou, Yue Huang, Scott Umlauf, Xiaoyu Chen
Publikováno v:
Antibodies, Vol 12, Iss 4, p 68 (2023)
Asparagine deamidation is a post-translational modification (PTM) that converts asparagine residues into iso-aspartate and/or aspartate. Non-enzymatic asparagine deamidation is observed frequently during the manufacturing, processing, and/or storage
Externí odkaz:
https://doaj.org/article/4a1c6cf978184bb1870f19d9d0c1a91e
Autor:
Jun Kim, Yoen Joo Kim, Mingyan Cao, Niluka De Mel, Kenneth Miller, Jared S. Bee, Jihong Wang, Xiangyang Wang, Methal Albarghouthi
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
When two therapeutic agents are combined in a single formulation, i.e., coformulated, the quality and safety of the individual agents must be preserved. Here we describe an approach to evaluate the quality attributes of two individual monoclonal anti
Externí odkaz:
https://doaj.org/article/c401e00aa0004b988ffc64c379fc550f
Autor:
Niluka De Mel, Weimin Chen, Greg Kilby, Dengfeng Liu, Conner Parthemore, Jihong Wang, Yang Jiao, Mingyan Cao, Shihua Lin, Xiaoyu Chen
Publikováno v:
Journal of Pharmaceutical Sciences. 111:335-344
N-terminal glutamate (E) cyclization to form pyroglutamate (pE) generates charge heterogeneities for mAbs and proteins. Thus far, pE formation rate in lyophilized formulation as compared to in liquid formulation has not been reported. Impact of pE on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::468749accdc115b5fa791181d256b41f
https://doi.org/10.1016/j.xphs.2021.09.006
https://doi.org/10.1016/j.xphs.2021.09.006
Autor:
Xiaojun Lu, Weichen Xu, Jihong Wang, Qun Du, Niluka De Mel, Michael Washabaugh, Xu-Rong Jiang, Lee Ann Machiesky
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-11 (2020)
Scientific Reports
Scientific Reports
Antibody-dependent cell-mediated cytotoxicity (ADCC) is an important mechanism of action for many therapeutic antibodies. A therapeutic immunoglobulin (Ig) G1 monoclonal antibody lost more than half of its ADCC activity after heat stress at 40 °C fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b2dc194f0e1ca4ed35e3eaa6f1d9c54
http://link.springer.com/article/10.1038/s41598-019-57184-2
http://link.springer.com/article/10.1038/s41598-019-57184-2
Autor:
Ben Niu, Michael Martinelli, Niluka de Mel, Eric Meinke, Weiguo Zhai, Greg Kilby, Wei Xu, Xiaoyu Chen, Chunlei Wang
Publikováno v:
Journal of chromatography. A. 1663
Therapeutic monoclonal antibodies (mAbs) are inherently heterogeneous and hence generally studied and controlled by an array of orthogonal separation methods. During drug candidate development, fractionation by HPLC is regularly employed to assist pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::081a981eac2ee5c8e19ec2d945bdd680
https://pubmed.ncbi.nlm.nih.gov/34968959
https://pubmed.ncbi.nlm.nih.gov/34968959
Autor:
Samuel A. Korman, Yang Jiao, Dengfeng Liu, Niluka De Mel, Mingyan Cao, James Howard, Christopher Thompson, Michaela Wendeler, Conner Parthemore
Publikováno v:
mAbs
Site-specific antibody-drug conjugates (ADCs) are designed to overcome the heterogeneity observed with first-generation ADCs that use random conjugation to surface-exposed lysine residues or conjugation to interchain disulfide bonds. Despite signific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b0555bb7219b44885ed355fe5697a75
https://doi.org/10.1080/19420862.2019.1624127
https://doi.org/10.1080/19420862.2019.1624127
Autor:
Dengfeng Liu, Niluka De Mel, Jun Kim, Shihua Lin, Jihong Wang, Anthony G. Shannon, Eric Meinke, Meagan Prophet, Chunlei Wang, Ben Niu, Xiangyang Wang, Methal Albarghouthi, Weichen Xu, Mingyan Cao
Publikováno v:
mAbs
© 2019, © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. Combination therapy is a fast-growing strategy to maximize therapeutic benefits to patients. Co-formulation of two or more therapeutic proteins has advantages over
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9514d6dc64285e178048682f9e8b98c6
https://doi.org/10.1080/19420862.2019.1578137
https://doi.org/10.1080/19420862.2019.1578137
Autor:
Mingyan Cao, Jared S. Bee, Jihong Wang, Niluka De Mel, Xiangyang Wang, Yoen Joo Kim, Kenneth Miller, Jun Kim, Methal Albarghouthi
Publikováno v:
mAbs
When two therapeutic agents are combined in a single formulation, i.e., coformulated, the quality and safety of the individual agents must be preserved. Here we describe an approach to evaluate the quality attributes of two individual monoclonal anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c864bc23120f6be4c15b508b9dce4e1
https://doi.org/10.1080/19420862.2020.1738691
https://doi.org/10.1080/19420862.2020.1738691